Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...

Humira has been dominating the space for almost ... The company's flagship products, Botox and Juvéderm, hold 60% and 40% market shares respectively in the U.S. toxins segment.

Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Humira sales fell 40% in the quarter and are expected to continue to slow due to competition from biosimilars. However, that is, in turn, offset by increased sales of key drugs Ubrelvy ...

Moderna, AbbVie, and Danaher are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares in companies that focus on developing and ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...

Some 40 per cent of its revenues come from consumer ... It has a small market share for its biosimilar of blockbuster Humira that is used to treat conditions including rheumatoid arthritis ...

Sandoz is one of the largest biosimilars players in the world and we believe it is well-positioned to benefit from the fast pace of growth the market is expected to enjoy over the next decade. Sandoz ...

Humira is a treatment for moderate to severe ... Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil. Abbott's presence in these high-growth ...